BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC [Seeking Alpha]
BeyondSpring, Inc. - Ordinary Shares (BYSI)
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.beyondspringpharma.com
Company Research
Source: Seeking Alpha
results as a treatment for non-small cell lung cancer after failure on a checkpoint inhibitor. Interim data from the single-arm, open-label phase 2 Study 303 based on 19 evaluable patients showed a confirmed objective response rate of 21.1%. Median progression-free survival was 67.1 after six months and 49.2% after a year. Patients enrolled previously progressed while on PD-1/L1 inhibitors. Results also found that 52.6% of patients experienced grade 3 or higher treatment-related adverse effects. BeyondSpring, which is developing plinabulin, intends to enrol 47 patients total in Study 303, which is taking place in China. The company closed down ~5% on Monday. Recommended For You More Trending News Recommended For You More Trending News Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
BYSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BYSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BYSI alerts
High impacting BeyondSpring, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
BYSI
News
- BeyondSpring sells stake in preferred shares of SEED Therapeutics for ~$35.4M [Seeking Alpha]Seeking Alpha
- SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New InvestorsGlobeNewswire
- BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational StudiesGlobeNewswire
BYSI
Sec Filings
- 2/14/25 - Form SCHEDULE
- 1/28/25 - Form 8-K
- 1/3/25 - Form 8-K
- BYSI's page on the SEC website